Roche Holding AG (RHHVF)
OTCMKTS · Delayed Price · Currency is USD
415.00
+9.25 (2.28%)
Jul 7, 2026, 2:24 PM EST
Roche Holding AG Revenue
In the year 2025, Roche Holding AG had annual revenue of 63.36B CHF with 1.54% growth. Roche Holding AG had revenue of 31.51B in the half year ending December 31, 2025, with 5.64% growth.
Revenue
63.36B CHF
Revenue Growth
+1.54%
P/S Ratio
4.20
Revenue / Employee
613.62K CHF
Employees
103,249
Market Cap
335.57B USD
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 63.36B | 961.00M | 1.54% |
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 594.41M |
| Vaxart | 255.61M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 148.87M |
| Northwest Biotherapeutics | 1.50M |
| Silence Therapeutics | 839.00K |
| Comjoyful International Company | 564.97K |
Roche Holding AG News
- 23 hours ago - Roche presents new data in Alzheimer's disease from across its integrated pharmaceutical and diagnostics portfolio at AAIC - GlobeNewsWire
- 23 hours ago - Genentech and Roche Present New Data in Alzheimer's Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC - Business Wire
- 5 days ago - Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial - WSJ
- 5 days ago - Genentech's Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer - Business Wire
- 5 days ago - [Ad hoc announcement pursuant to Art. 53 LR] Roche's divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer - GlobeNewsWire
- 6 days ago - Old cancer drug may help restore fertility for certain women - Reuters
- 7 days ago - FDA Grants Priority Review To Genentech's Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED) - Business Wire
- 8 days ago - Roche launches Axelios gene sequencer in a bid to loosen Illumina's grip - Reuters